Global COVID-19 treatment trial shows current antivirals are of little benefit to hospitalized patients
The World Health Organization’s (WHO) Solidarity Trial, with sites in 30 countries and over 11,000 patients in 405 hospitals, has concluded that several antivirals thought to hold promise in treating COVID-19 were not effective at reducing 28-day mortality or changing the course of hospitalized patients’ illness. The drugs studied were remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens.
Published: October 16, 2020
UBC Faculty of MedicineRead Article